Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4muscarinic acetylcholine receptor
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE We recently characterized LY2033298 as a novel allosteric modulator and agonist at M 4 muscarinic acetylcholine receptors (mAChRs). Evidence also suggested a difference in the potency of LY2033298 at rodent relative to human M 4 mAChRs. The current study investigated the basis for the species difference of this modulator and used this knowledge to rationalize its in vivo actions. EXPERIMENTAL APPROACH LY2033298 was investigated in vitro in CHO cells stably expressing human or mouse M 4 mAChRs, using assays of agonist‐induced ERK1/2 or GSK‐3α phosphorylation, [35 S]‐GTPγS binding, or effects on equilibrium binding of [3 H]‐NMS and ACh. The in vivo actions of LY2033298 were investigated in a mouse model of amphetamine‐induced locomotor activity. The function of LY2033298 was examined in combination with ACh, oxotremorine or xanomeline. KEY RESULTS LY2033298 had similar affinities for the human and mouse M 4 mAChRs. However, LY2033298 had a lower positive co‐operativity with ACh at the mouse relative to the human M 4 mAChR. At the mouse M 4 mAChR, LY2033298 showed higher co‐operativity with oxotremorine than with ACh or xanomeline. The different degrees of co‐operativity between LY2033298 and each agonist at the mouse relative to the human M 4 mAChR necessitated the co‐administration of LY2033298 with oxotremorine in order to show in vivo efficacy of LY2033298. CONCLUSIONS AND IMPLICATIONS These results provide evidence for species variability when comparing the allosteric interaction between LY2033298 and ACh at the M 4 mAChR, and also highlight how the interaction between LY2033298 and different orthosteric ligands is subject to ‘probe dependence’. This has implications for the validation of allosteric modulator actions in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
The role of acetylcholine in learning and memory
Hasselmo, M. E. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.09.002 · Cited by 1,693
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 3×
“This demonstrates an ongoing need for alternative and/or complementary approaches to the current clinical armamentarium in the treatment of schizophrenia, which consists predominantly of typical antipsychotics, such as haloperidol, atypical antipsychotics, such as clozapine, and third generation agents, such as aripip…”
BackgroundInfluentialZhang, W., Yamada, M., Gomeza, J., Basile, A. S., & Wess, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06347.2002 · Cited by 224
Cited by
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Self-citationMuscarinic acetylcholine receptors: novel opportunities for drug development
Kruse, A. C., Kobilka, B. K., Gautam, D., Sexton, P. M., Christopoulos, A., & Wess, J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4295 · Cited by 437
Self-citationCrystal structures of the M1 and M4 muscarinic acetylcholine receptors
Thal, D. M., Sun, B., Feng, D., Nawaratne, V., Leach, K., Felder, C. C., Bures, M. G., Evans, D. A., Weis, W. I., Bachhawat, P., et al. (2016) · Nature · doi:10.1038/nature17188 · Cited by 335
Self-citationConn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4308 · Cited by 260
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63
“In addition, LY2033298 did not potentiate ACh at the rodent M4 mAChR to the same extent as at the human M4 mAChR, indicating that there is species variability in the modulatory responses at the M4 mAChR (Chan et al., 2008; Suratman et al., 2011).”
BackgroundSelf-citation
Metadata
- Authors
- Suratman, S., Leach, K., Sexton, P., Felder, C., Loiacono, R., & Christopoulos, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-03-04
- Volume
- 162
- Issue
- 7
- Pages
- 1659-1670
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1488907461
- Cited by
- 68
- References
- 7
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4muscarinic acetylcholine receptor. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.01184.x
- The paper
- Suratman, S., Leach, K., Sexton, P., Felder, C., Loiacono, R., & Christopoulos, A. (2011). Impact of species variability and ‘probe‐dependence’ on the detection and in vivo validation of allosteric modulation at the M4muscarinic acetylcholine receptor. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.01184.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.